GC BIOPHARMA

Serial Number 97298515
733

Registration Progress

Application Filed
Mar 7, 2022
Under Examination
Feb 7, 2023
Approved for Publication
Dec 13, 2022
Published for Opposition
Dec 13, 2022
Registered

Attorney Assistance

Important Deadline Approaching
Statement of Use Due - Extension 4 Granted
Due: August 07, 2025 31 days remaining

Missing this deadline could result in abandonment or cancellation of your trademark.

What would you like to file?

Basic Information

Serial Number
97298515
Deadline
August 7, 2025
Description
Statement of Use or 5th Extension Due
Filing Date
March 7, 2022
Published for Opposition
December 13, 2022
Drawing Code
3

Status Summary

Current Status
Active
Status Code
733
Status Date
Feb 5, 2025
Application
Pending
Classes
005 035 042

Rights Holder

Green Cross Holdings Corporation

03
Address
107, Ihyeon-ro 30beon-gil, Giheung-gu,
Yongin-si, Gyeonggi-do 16924
KR

Ownership History

Green Cross Holdings Corporation

Original Applicant
03
Yongin-si, Gyeonggi-do KR

Green Cross Holdings Corporation

Owner at Publication
03
Yongin-si, Gyeonggi-do KR

Legal Representation

Attorney
Kwang Yup Chae

USPTO Deadlines

Next Deadline
31 days remaining
Statement of Use Due - Extension 4 Granted
Due Date
August 07, 2025
Extension Available
Until February 07, 2024

Application History

30 events
Date Code Type Description
May 8, 2025 EISU I TEAS STATEMENT OF USE RECEIVED
Feb 5, 2025 EX4G S SOU EXTENSION 4 GRANTED
Feb 5, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 5, 2025 EEXT I SOU TEAS EXTENSION RECEIVED
Feb 5, 2025 EXT4 S SOU EXTENSION 4 FILED
Jul 24, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 22, 2024 EXT3 S SOU EXTENSION 3 FILED
Jul 22, 2024 EX3G S SOU EXTENSION 3 GRANTED
Jul 22, 2024 EEXT I SOU TEAS EXTENSION RECEIVED
Jan 19, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 17, 2024 EXT2 S SOU EXTENSION 2 FILED
Jan 17, 2024 EEXT I SOU TEAS EXTENSION RECEIVED
Jan 17, 2024 EX2G S SOU EXTENSION 2 GRANTED
Mar 18, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 16, 2023 EEXT I SOU TEAS EXTENSION RECEIVED
Mar 16, 2023 EX1G S SOU EXTENSION 1 GRANTED
Mar 16, 2023 EXT1 S SOU EXTENSION 1 FILED
Feb 7, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 13, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 13, 2022 PUBO A PUBLISHED FOR OPPOSITION
Nov 23, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 4, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 4, 2022 XAEC I EXAMINER'S AMENDMENT ENTERED
Nov 4, 2022 GNEA F EXAMINERS AMENDMENT E-MAILED
Nov 4, 2022 CNEA R EXAMINERS AMENDMENT -WRITTEN
Nov 4, 2022 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 28, 2022 DOCK D ASSIGNED TO EXAMINER
Mar 12, 2022 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED
Mar 11, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 10, 2022 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Medicines for humans used for the prevention and treatment of cancer, cerebrovascular thrombosis, myocardial infarctions, peripheral artery occlusions, pulmonary embolisms, thrombocytopenia, thrombophlebitis, Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Immunodeficiency disease, Human Immunodeficiency Virus, rare disease, Hunter Syndrome, Hemophilia, Hemophilia A, arthritis, osteoarthritis, arthritis deformans, periarthritis humeroscapularis, tendinitis, peritendinitis, humeral epicondylitis, idiopathic thrombocytopenic purpura, Guillain-barre syndrome, Kawasaki syndrome, Clostridium tetani, virus infection, influenza, bacterial infection and chronic pain; Medicines for humans, namely, blood plasma-derivatives, namely, albumins, immunoglobulins, and blood clotting factors; Medicated plasters; Vaccines; Biological preparations for medical or veterinary purposes, namely, biological preparations used for the prevention and treatment of cancer, cerebrovascular thrombosis, myocardial infarctions, peripheral artery occlusions, pulmonary embolisms, thrombocytopenia, thrombophlebitis, Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Immunodeficiency disease, Human Immunodeficiency Virus, rare disease, Hunter Syndrome, Hemophilia, Hemophilia A, arthritis, osteoarthritis, arthritis deformans, periarthritis humeroscapularis, tendinitis, peritendinitis, humeral epicondylitis, idiopathic thrombocytopenic purpura, Guillain-barre syndrome, Kawasaki syndrome, Clostridium tetani, virus infection, influenza, bacterial infection and chronic pain; Biological preparations for medical or veterinary purposes, namely, blood plasma-derivatives, namely, albumins, immunoglobulins, and blood clotting factors; Dietary and nutritional supplements
Class 035
Wholesale distributorships and retail store services featuring pharmaceutical products; Export and import agencies in the field of pharmaceutical products; Wholesale store services featuring biological preparations for medical purposes; Retail store services featuring biological preparations for medical purposes; Retail store services featuring pharmaceutical preparations for the treatment of cells; Retail store services featuring medical instruments; Retail store services featuring medical apparatus; Retail store services featuring medical genetic analyzer; Retail store services featuring electromedical diagnostic instruments; Wholesale store services featuring pharmaceutical preparations for the treatment of cells; Wholesale store services featuring medical instruments; Wholesale store services featuring medical apparatus; Wholesale store services featuring medical genetic analyzer; Wholesale store services featuring electromedical diagnostic instruments; all the foregoing excluding services in the field of industrial, institutional, commercial and janitorial equipment and supplies; Financial intermediary services, namely, facilitating the channeling of funds between lenders and borrowers by connecting those with a financial surplus with those having a financial deficit in the field of pharmaceutical products and medical equipment; Operation of a business for others, namely, wholesale distributorships and retail stores featuring pharmaceutical products; Procurement, namely, purchasing pharmaceutical products for other businesses
Class 042
Research and development of vaccines and medicines; Research and development, laboratory and scientific research in the field of pharmaceuticals, blood plasma preparations, recombinant proteins and antibodies; Conducting clinical studies of medicines for medical research purposes; Clinical research in the nature of performing biopsies for medical research; Product research and development of medical products; Conducting technical project studies, namely, engineering services in the nature of technical project planning and design engineering of medical products; Testing, inspection or research of pharmaceuticals; Scientific research relating to biology; Scientific research in the field of genetic engineering; Research and development of technology for biotechnology; Scientific research in the fields of biomedicine; Laboratory research in the field of biology; Product development of cell therapy products; Drug discovery services; Research and development in the pharmaceutical and biotechnology fields; Scientific research in the field of gene analysis; Medical studies, namely, medical laboratory services; Research and development of technology for medicinal chemical manufacturing; Medical research services relating to clinical data

Additional Information

Design Mark
The mark consists of a stylized rounded cross with the top and right arms in red fading toward the middle to orange then to yellow, and the left and lower arms in green; to the right of the cross are the stylized wording "GC Biopharma" in dark blue; the color white is not claimed as a feature of the mark and represents background and transparent areas only.
Color Claim
The color(s) green, yellow, orange, red, and dark blue is/are claimed as a feature of the mark.

Classification

International Classes
005 035 042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOPHARMA"